TechnoPhage, SA - From science to innovative biopharmaceuticals

TechnoPhage receives FDA clearance to begin human clinical trials of an innovative biological therapeutic

TECHNOPHAGE, a biotechnology company headquartered in Lisbon, Portugal, announced today that the company has received authorization from U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for TP-102, a bacteriophage cocktail for the treatment of infected chronic ulcers, namely diabetic foot infections. This clearance will enable TechnoPhage to initiate trials in humans, confirming safety and efficacy of these therapeutics which has already been assessed in laboratory environment. At the moment, no current topical therapy is available specifically targeted at chronic diabetic foot infections. Therefore, TechnoPhage will address an unmet medical need with great impact on the wellbeing of these patients.

2019 events

18th Fraunhofer Seminar "Models of Lung Disease"
Hannover, Germany. January 24 - 25, 2019

Phage Futures Congress
Washington DC. January 29-30, 2019

Bacteriophage Therapy Summit
Boston, MA. March 26-27, 2019

29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Amsterdam, Netherlands. April 13-16, 2019